The following are some of the U.S. FDA’s actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA is facilitating access to convalescent plasma, antibody-rich blood products taken from blood donated by people who have recovered from the COVID-19 virus, that could shorten the length, or lessen the severity, of the illness. The agency will be using multiple pathways to support these efforts and has posted information for investigators wishing to study convalescent pl...